146 related articles for article (PubMed ID: 22918125)
1. Raltegravir-based regimens are effective in HIV-1 group O-infected patients.
Depatureaux A; Leoz M; Le Moal G; Pathé JP; Pavie J; Batisse D; Daneluzzi V; Genet P; Gerard L; Lascaux-Cametz AS; Lambolez T; Chennebault JM; Plantier JC
J Acquir Immune Defic Syndr; 2012 Sep; 61(1):e1-3. PubMed ID: 22918125
[No Abstract] [Full Text] [Related]
2. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
[No Abstract] [Full Text] [Related]
3. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
McMahon D; Jones J; Wiegand A; Gange SJ; Kearney M; Palmer S; McNulty S; Metcalf JA; Acosta E; Rehm C; Coffin JM; Mellors JW; Maldarelli F
Clin Infect Dis; 2010 Mar; 50(6):912-9. PubMed ID: 20156060
[TBL] [Abstract][Full Text] [Related]
4. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Nozza S; Galli L; Bigoloni A; Nicola G; Pogliaghi M; Cossarini F; Salpietro S; Galli A; Della Torre L; Tambussi G; Lazzarin A; Castagna A
J Acquir Immune Defic Syndr; 2011 Apr; 56(4):e113-5. PubMed ID: 21350358
[No Abstract] [Full Text] [Related]
5. Raltegravir: is a 400 mg once-daily dose enough?
Lanzafame M; Hill A; Lattuada E; Calcagno A; Bonora S
J Antimicrob Chemother; 2010 Mar; 65(3):595-7. PubMed ID: 20071368
[No Abstract] [Full Text] [Related]
6. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
7. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
[TBL] [Abstract][Full Text] [Related]
8. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
[No Abstract] [Full Text] [Related]
9. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
Wittkop L; Breilh D; Da Silva D; Duffau P; Mercié P; Raymond I; Anies G; Fleury H; Saux MC; Dabis F; Fagard C; Thiébaut R; Masquelier B; Pellegrin I;
J Antimicrob Chemother; 2009 Jun; 63(6):1251-5. PubMed ID: 19336453
[TBL] [Abstract][Full Text] [Related]
10. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
Gotuzzo E; Markowitz M; Ratanasuwan W; Smith G; Prada G; Morales-Ramirez JO; Strohmaier KM; Lu C; Bhanja S; Nguyen BY; Teppler H;
J Acquir Immune Defic Syndr; 2012 Sep; 61(1):73-7. PubMed ID: 22743596
[TBL] [Abstract][Full Text] [Related]
11. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
Monteiro P; Perez I; Pich J; Gatell JM; Martínez E
J Antimicrob Chemother; 2013 Feb; 68(2):404-8. PubMed ID: 23109185
[TBL] [Abstract][Full Text] [Related]
12. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
Gatell JM; Katlama C; Grinsztejn B; Eron JJ; Lazzarin A; Vittecoq D; Gonzalez CJ; Danovich RM; Wan H; Zhao J; Meibohm AR; Strohmaier KM; Harvey CM; Isaacs RD; Nguyen BY;
J Acquir Immune Defic Syndr; 2010 Apr; 53(4):456-63. PubMed ID: 20306554
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
Lanzafame M; Lattuada E; Rigo F; Nicole S; Cucchetto G; Vento S
AIDS; 2015 Aug; 29(13):1722-3. PubMed ID: 26372286
[No Abstract] [Full Text] [Related]
15. Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens.
Edwards JK; Cole SR; Hall HI; Mathews WC; Moore RD; Mugavero MJ; Eron JJ;
AIDS; 2018 Jan; 32(2):261-266. PubMed ID: 29112076
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
Meditz AL; Palmer C; Predhomme J; Searls K; Kerr B; Seifert S; Caraway P; Gardner EM; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2015 Oct; 31(10):1015-22. PubMed ID: 26059647
[TBL] [Abstract][Full Text] [Related]
17. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
[TBL] [Abstract][Full Text] [Related]
18. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
[TBL] [Abstract][Full Text] [Related]
19. Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy.
Noguera-Julian M; Casadellà M; Pou C; Rodríguez C; Pérez-Álvarez S; Puig J; Clotet B; Paredes R
Virol J; 2013 Dec; 10():350. PubMed ID: 24304606
[TBL] [Abstract][Full Text] [Related]
20. Poorer immunologic outcome on treatment among patients infected with HIV-1 non-B subtypes compared with subtype B in Singapore.
Lee LK; Lin L; Chua A; Leo YS; Ng OT
Clin Infect Dis; 2012 Jun; 54(12):1818-20. PubMed ID: 22423124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
